U.S FDA warning about Desmopressin Nasal Spray:

I was reading the ‘Medscape’ medical news few minutes ago, found out this article intresting and latest. According to this news,

Us food and Drug Administration (FDA) warned healthcare professionals yesterday that Desmopressin acetate intranasal formulations are no longer indicated for the treatment of primary nocturnal enuresis (PNE) because of the risk for severe hyponatremia that can lead to seizures and death. This decision was made based on a review of data from 61 postmarketing cases of hyponatremia-related seizures.
Desmopressin nasal Spray is currently marketed as DDAVP, MINIRIN and STIMATE.
According to MedWatch, the FDA’s safety information and adverse event reporting program, Desmopressin tablets may still be used for primary nocturnal enuresis, however, treatment should be interrupted during acute illnesses that can lead to fluid and/or electrolyte imbalance.

The FDA also emphasized that fluid intake should be restricted from 1 hour before to 8 hours following dose administration and that all desmopressin formulations should be used cautiously in patients at risk for water intoxication with hyponatremia.
I have not read anything about it from Health canada yet.......may be soon...